coin-img-ETHETH+3.92%coin-img-BTCBTC+1.04%coin-img-SOLSOL+2.05%coin-img-USDCUSDC+0.00%coin-img-XRPXRP+0.47%coin-img-DOGEDOGE-0.95%coin-img-TRXTRX-0.57%coin-img-BNBBNB+0.37%coin-img-ETHETH+3.92%coin-img-BTCBTC+1.04%coin-img-SOLSOL+2.05%coin-img-USDCUSDC+0.00%coin-img-XRPXRP+0.47%coin-img-DOGEDOGE-0.95%coin-img-TRXTRX-0.57%coin-img-BNBBNB+0.37%coin-img-ETHETH+3.92%coin-img-BTCBTC+1.04%coin-img-SOLSOL+2.05%coin-img-USDCUSDC+0.00%coin-img-XRPXRP+0.47%coin-img-DOGEDOGE-0.95%coin-img-TRXTRX-0.57%coin-img-BNBBNB+0.37%coin-img-ETHETH+3.92%coin-img-BTCBTC+1.04%coin-img-SOLSOL+2.05%coin-img-USDCUSDC+0.00%coin-img-XRPXRP+0.47%coin-img-DOGEDOGE-0.95%coin-img-TRXTRX-0.57%coin-img-BNBBNB+0.37%
user-avatar
Moneycontrol

Motilal Oswal reiterates buy on Laurus Labs with INR1,980 target

AI Market Summary
Laurus Labs reported a strong 1QFY27 earnings beat, with revenue, EBITDA, and net profit exceeding expectations on CDMO and formulations strength. Commercial and late-stage clinical supplies, plus a customer's global regulatory approval, improve order visibility and support continued manufacturing investment. The news is equity-specific and signals improving operating leverage and demand durability, but has limited broader cross-asset market impact.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+0.84%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Laurus Labs reported 1QFY27 results, with revenue, EBITDA and net profit beating market expectations by 14%, 31% and 53%, respectively, marking a record quarter. The growth was led by its CDMO and formulations (FDF) businesses, supported by commercial supplies and deliveries for late-stage clinical projects. It also cited improved order visibility after a customer received global regulatory approval for a product, according to Motilal Oswal. Based on this, the brokerage set a target price of INR1,980, valuing the stock at 65x forward earnings.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.